首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % HPLC. |
| 种属 | Human |
| 靶点 | CCL1 |
| Uniprot No | P22362 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-96aa |
| 氨基酸序列 | KSMQVPFSRCCFSFAEQEIPLRAILCYRNTSSICSNEGLIFKLKRGKEAC ALDTVGWVQRHRKMLRHCPSKRK |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL1重组蛋白的3篇参考文献示例(部分信息为虚构示例，供参考)：
---
1. **标题**: "Expression and functional characterization of recombinant human CCL1 in inflammatory models"
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌系统成功表达并纯化重组人CCL1蛋白，验证其趋化活性可诱导单核细胞迁移，并发现其在慢性炎症小鼠模型中加剧Th2型免疫反应。
2. **标题**: "Structural analysis of CCL1-CCR8 interaction reveals key motifs for receptor activation"
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析CCL1重组蛋白与受体CCR8的结合结构，发现其N端α-螺旋对受体激活至关重要，为靶向CCL1/CCR8轴的药物设计提供依据。
3. **标题**: "Recombinant CCL1 promotes tumor-associated macrophage infiltration in breast cancer"
**作者**: Kim H, et al.
**摘要**: 体外实验表明，重组CCL1通过激活ERK信号通路增强肿瘤相关巨噬细胞(TAMs)的侵袭能力，提示其在肿瘤微环境中的潜在促癌作用。
---
(注：若需真实文献，建议通过PubMed或Web of Science检索关键词“recombinant CCL1”或“CCL1 protein”获取。)
CCL1 (C-C motif chemokine ligand 1), also known as I-309 or TCA-3 in rodents, is a small cytokine belonging to the CC chemokine family. It functions as a chemoattractant for immune cells, including monocytes, dendritic cells, and activated T lymphocytes, by binding to its specific receptor CCR8. CCL1 is primarily produced by activated T cells, macrophages, and certain tumor cells, playing roles in immune regulation, inflammation, and tumor microenvironment modulation. Its expression is upregulated in Th2-associated conditions, such as allergic responses and parasitic infections, as well as in malignancies like Hodgkin’s lymphoma and breast cancer.
Recombinant CCL1 is engineered through genetic cloning and expression in heterologous systems (e.g., *E. coli*, yeast, or mammalian cells) to produce high-purity, bioactive protein for research and therapeutic applications. The recombinant form typically retains the conserved 8-cysteine motif critical for chemokine structure and receptor interaction. Mammalian expression systems are often preferred to ensure proper post-translational modifications, such as glycosylation, which may influence receptor binding and stability.
Studies using recombinant CCL1 have elucidated its involvement in promoting tumor progression via angiogenesis and immune evasion, as well as its dual role in pro-inflammatory and immunosuppressive pathways. It serves as a tool for investigating CCR8 signaling mechanisms, including PI3K/Akt and MAPK pathways, and for screening antagonists targeting the CCL1/CCR8 axis in cancer immunotherapy. Additionally, recombinant CCL1 aids in modeling immune cell trafficking *in vitro* and in preclinical disease models, offering insights into therapeutic strategies for autoimmune disorders, chronic inflammation, and infectious diseases.
×
